Can nTregs Minimize Immunosuppression after Kidney Transplant?

Restricted access

An approach using autologous natural regulatory T cells (nTregs) appears safe and feasible for minimizing immune suppression after kidney transplantation, according to a phase I/IIa clinical trial in The British Medical Journal.

The researchers report an initial experience with their “in-house” autologous CD4+CD25+FoxP3+ nTreg product in 11 living kidney donor transplant recipients. The nTreg product was administered 7 days posttransplant in a single intravenous dose of 0.5, 1.0, or 2.5 to 3.0 × 106 cells/kg. After treatment, the investigators attempted stepwise tapering of standard triple immunosuppression to low-dose tacrolimus monotherapy up to week 48.

A composite

Save